Business Wire

Climate Change Tops the Agenda for Institutional Investors in 2021

Share

When institutional investors with USD 29 trillion in assets under management were asked what issue was most likely to prompt them to engage with company boards, climate change topped the agenda.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005108/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Thank you for your interest in our insight! (Graphic: Business Wire)

This is among the key findings of the 2021 Institutional Investor Survey by Morrow Sodali, released today.

The annual global poll of over 40 institutional investors aims to find out what is really important for them when analyzing companies, and to highlight their main areas of focus in determining how to exercise their voting rights at ongoing shareholder meetings.

Survey questions are designed to identify the latest trends in company engagement, including ESG (Environmental, Social and Governance) and sustainability, remuneration and AGM-related issues, and shareholder activism.

The 2021 iteration of the survey, which is now in its 6th year, underscores how the focus on ESG continues to intensify. The institutions surveyed see a clear link between ESG performance and good financial performance, and they want companies to improve their engagement and reporting on these topics.

While these include issues such as board composition, executive remuneration and human capital management, which are all being looked at more closely than ever before, climate change tops the agenda in terms of prompting investors to engage. The survey findings indicate that there is ample room for improvement in the quality of corporate ESG reporting, and investors in particular, want companies to discuss these topics in the context of their business plans. Companies should ensure that they have the right people engaging, in terms of both management and the board, and that these representatives are properly prepared to discuss the relevant issues.

Investors expect to see links between climate change and financial risks and opportunities identified, time horizons of the expected impact of climate change on corporate strategies explained, and metrics, targets and achievements clearly disclosed. With climate risk so clearly at the forefront of investors’ minds, it comes as no surprise that TCFD far outpaced other reporting frameworks as the first choice of 75% of respondents.

The survey highlights a strong uptick in the popularity of TCFD, and many investors now expect companies to either align with it or explain why they believe it is not necessary. SAS3 was the second choice, and it was interesting to see that a large proportion of respondents (39%) reported using in-house proprietary frameworks. This is a message to the market that investors are becoming much more sophisticated in this regard.

The survey revealed that statements of company purpose are considered to be one of the driving forces behind creating sustainable long-term value, with a strong majority (86%) of investor respondents agreeing that every company should disclose its corporate purpose, and a substantial proportion (20%) saying the issue could lead them to vote against the board chair or other directors.

ESG is now firmly established as a key factor in how investors evaluate company strategy and performance, and predictably the overwhelming majority (95%) of respondents wanted to see it incorporated into executive incentive plans. Trends from past years show that investors wanted to see a proportion of incentives tied to sustainability measures, and when drilled down in 2021, the result is a strong consensus (69%) felt that 5–25% was a reasonable amount.

Particularly noteworthy was the response on annual incentives, where the survey showcases a significant upturn in support (95%) for the inclusion of sustainability performance metrics in short-term incentive plans. By comparison, when investors were asked how important they found ESG performance metrics in short-term incentive programs in 2018, 29% said ‘not important’ and an additional 8% had no opinion. This does raise interesting questions around which ESG targets can credibly be included in annual incentives, as that clearly is not the case for all types of metrics.

For the last three years, the Morrow Sodali survey has asked investors: “What would lead you to vote against executive remuneration proposals?’’, and they have consistently indicated “misalignment of pay and performance” to be their primary concern. This year, the survey sought to examine this issue more deeply by asking what they considered the key indicators of such misalignment to be.

In response, investors identified incentive plans without performance hurdles (63%), bonuses paid by companies while severely impacted by COVID-19 (46%) and the adoption of discretionary variable pay programs (29%) as their key concerns.

Shareholder activism continues to evolve in 2021, and the survey reflected growing investor support for activist campaigns, both traditional and ESG-related. While most investors believe engaging with board members is the most effective way to influence boards, collaboration with other shareholders is rapidly becoming more acceptable. In 2021, 86% of respondents either “strongly agreed” or “somewhat agreed” that collaboration with other shareholders is an effective way to influence boards, a significant increase compared to the 2018 survey result (12%).

Aside from poor financial performance, poor strategic decisions were the factor most likely to lead an investor to support an activist. When asked what ESG factors might lead them to support an activist, 66% of respondents identified a lack of response to an ESG shareholder resolution as the most pressing issue.

Last year the survey proposed a slightly different but similar question about how investors would seek to influence boards to pay more attention to ESG issues, and this option received only 21% support. It is notable that the support for this option has increased dramatically in 2021. This clearly reflects the overarching theme of investor responses this year: the increasingly sharp focus on climate change at a global level.

To see the full results of Morrow Sodali’s Institutional Investor Survey 2021, visit here.

ABOUT MORROW SODALI

Morrow Sodali is a leading provider of strategic advice and shareholder services to corporate clients around the world. The firm provides corporate boards and executives with strategic advice and services relating to corporate governance, shareholder and bondholder communication and engagement, capital markets intelligence, proxy solicitation, shareholder activism and mergers and acquisitions.

From headquarters in New York and London, and offices and partners in major capital markets, Morrow Sodali serves more than 700 corporate clients in 80+ countries, including many of the world’s largest multinational corporations. In addition to listed and private companies, its clients include financial institutions, mutual funds, ETFs, stock exchanges and membership associations.

For further information about Morrow Sodali, please visit www.morrowsodali.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elena Cargnello
Corporate Director of Marketing
+44 204 5136913
e.cargnello@morrowsodali.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye